Advaxis, Inc., a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.

Read more here:
FDA grants Orphan Drug Designation to Advaxis’ ADXS-HPV for treatment of invasive cervical cancer

Scroll to Top